vs
Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $183.6M, roughly 1.1× ACV Auctions Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 15.1%). ACV Auctions Inc. produced more free cash flow last quarter ($-14.7M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 12.3%).
ACV Auctions Inc.ACVAEarnings & Financial Report
ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ACVA vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.6M | $196.0M |
| Net Profit | — | $-28.6M |
| Gross Margin | — | — |
| Operating Margin | -9.7% | -13.8% |
| Net Margin | — | -14.6% |
| Revenue YoY | 15.1% | 65.0% |
| Net Profit YoY | — | 61.9% |
| EPS (diluted) | $-0.12 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.6M | $196.0M | ||
| Q3 25 | $199.6M | $171.0M | ||
| Q2 25 | $193.7M | $150.0M | ||
| Q1 25 | $182.7M | $121.5M | ||
| Q4 24 | $159.5M | $118.8M | ||
| Q3 24 | $171.3M | $104.8M | ||
| Q2 24 | $160.6M | $87.2M | ||
| Q1 24 | $145.7M | $75.0M |
| Q4 25 | — | $-28.6M | ||
| Q3 25 | $-24.5M | $-47.2M | ||
| Q2 25 | $-7.3M | $-48.0M | ||
| Q1 25 | $-14.8M | $-59.4M | ||
| Q4 24 | — | $-74.9M | ||
| Q3 24 | $-16.0M | $-64.6M | ||
| Q2 24 | $-17.1M | $-79.3M | ||
| Q1 24 | $-20.5M | $-68.4M |
| Q4 25 | -9.7% | -13.8% | ||
| Q3 25 | -11.9% | -27.0% | ||
| Q2 25 | -3.7% | -24.5% | ||
| Q1 25 | -7.9% | -46.9% | ||
| Q4 24 | -16.2% | -61.1% | ||
| Q3 24 | -10.0% | -59.8% | ||
| Q2 24 | -11.6% | -89.5% | ||
| Q1 24 | -15.5% | -89.7% |
| Q4 25 | — | -14.6% | ||
| Q3 25 | -12.3% | -27.6% | ||
| Q2 25 | -3.8% | -32.0% | ||
| Q1 25 | -8.1% | -48.9% | ||
| Q4 24 | — | -63.1% | ||
| Q3 24 | -9.4% | -61.7% | ||
| Q2 24 | -10.6% | -91.0% | ||
| Q1 24 | -14.1% | -91.1% |
| Q4 25 | $-0.12 | $-0.55 | ||
| Q3 25 | $-0.14 | $-0.94 | ||
| Q2 25 | $-0.04 | $-0.97 | ||
| Q1 25 | $-0.09 | $-1.22 | ||
| Q4 24 | $-0.15 | $-1.54 | ||
| Q3 24 | $-0.10 | $-1.34 | ||
| Q2 24 | $-0.10 | $-1.67 | ||
| Q1 24 | $-0.13 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.5M | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $429.7M | $88.3M |
| Total Assets | $1.1B | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.5M | $322.9M | ||
| Q3 25 | $265.3M | $325.3M | ||
| Q2 25 | $258.4M | $303.0M | ||
| Q1 25 | $291.9M | $300.9M | ||
| Q4 24 | $224.1M | $315.4M | ||
| Q3 24 | $252.5M | $327.3M | ||
| Q2 24 | $215.0M | $315.7M | ||
| Q1 24 | $209.8M | $331.4M |
| Q4 25 | $429.7M | $88.3M | ||
| Q3 25 | $434.4M | $73.7M | ||
| Q2 25 | $448.8M | $73.1M | ||
| Q1 25 | $439.6M | $53.2M | ||
| Q4 24 | $440.0M | $57.0M | ||
| Q3 24 | $456.2M | $92.9M | ||
| Q2 24 | $457.6M | $102.9M | ||
| Q1 24 | $458.3M | $144.0M |
| Q4 25 | $1.1B | $689.8M | ||
| Q3 25 | $1.2B | $669.3M | ||
| Q2 25 | $1.1B | $639.8M | ||
| Q1 25 | $1.2B | $596.7M | ||
| Q4 24 | $984.1M | $568.5M | ||
| Q3 24 | $1.0B | $561.5M | ||
| Q2 24 | $1.0B | $548.2M | ||
| Q1 24 | $1.0B | $545.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.4M | $-18.7M |
| Free Cash FlowOCF − Capex | $-14.7M | $-18.7M |
| FCF MarginFCF / Revenue | -8.0% | -9.6% |
| Capex IntensityCapex / Revenue | 1.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $69.1M | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.4M | $-18.7M | ||
| Q3 25 | $10.3M | $1.0M | ||
| Q2 25 | $13.7M | $-32.4M | ||
| Q1 25 | $66.6M | $-43.4M | ||
| Q4 24 | $-3.2M | $-26.2M | ||
| Q3 24 | $21.1M | $-18.6M | ||
| Q2 24 | $4.5M | $-30.1M | ||
| Q1 24 | $43.0M | $-53.5M |
| Q4 25 | $-14.7M | $-18.7M | ||
| Q3 25 | $7.7M | $988.0K | ||
| Q2 25 | $10.9M | $-32.4M | ||
| Q1 25 | $65.3M | $-43.7M | ||
| Q4 24 | $-3.9M | $-26.2M | ||
| Q3 24 | $20.2M | $-18.7M | ||
| Q2 24 | $2.7M | $-30.2M | ||
| Q1 24 | $41.9M | $-53.6M |
| Q4 25 | -8.0% | -9.6% | ||
| Q3 25 | 3.8% | 0.6% | ||
| Q2 25 | 5.6% | -21.6% | ||
| Q1 25 | 35.7% | -36.0% | ||
| Q4 24 | -2.5% | -22.1% | ||
| Q3 24 | 11.8% | -17.9% | ||
| Q2 24 | 1.7% | -34.6% | ||
| Q1 24 | 28.8% | -71.4% |
| Q4 25 | 1.2% | 0.0% | ||
| Q3 25 | 1.3% | 0.0% | ||
| Q2 25 | 1.5% | 0.0% | ||
| Q1 25 | 0.7% | 0.3% | ||
| Q4 24 | 0.4% | 0.0% | ||
| Q3 24 | 0.6% | 0.1% | ||
| Q2 24 | 1.1% | 0.1% | ||
| Q1 24 | 0.7% | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACVA
| Auction Marketplace Revenue | $77.6M | 42% |
| Other Marketplace Revenue | $72.4M | 39% |
| Customer Assurance | $24.1M | 13% |
| Data Services Revenue | $9.4M | 5% |
AXSM
Segment breakdown not available.
